IgGenix Demonstrated Potential for Single-Cell RNA-Sequencing to Address Shellfish Allergies at the 2023 AAAAI Annual Meeting

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–IgGenix, Inc., a pre-clinical antibody discovery and development company taking a revolutionary approach to directly address allergic disease, recently presented insights into the potential for IgE antibody re-engineering in shellfish allergy. These data, generated using IgGenix’s novel patented SEQ SIFTER™ single-cell RNA-sequencing discovery platform, were presented on February 26 during the 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, which took place in San Antonio, Texas on February 24-27, 2023.

“Individuals with severe forms of allergic disease have evolved potent IgE responses to otherwise innocuous antigens,” said Ben Chih-Pin Chung, Ph.D., Principal Scientist at IgGenix who presented the findings. “The high affinity and human origin of these antibodies make them promising leads for the future development of IgG allergen-specific therapies with the potential for enhanced efficacy, safety, and onset of action.”

Data Highlights

• IgGenix’s optimized single-cell RNA sequencing platform, SEQ SIFTER™, enabled the unbiased discovery of high-affinity IgE antibodies against shellfish, including crustaceans (such as shrimp, crab, and lobster) and mollusks (such as clams, mussels, and oysters).
• Monoclonal antibodies (mAbs) derived from patients cross-reacted with several shellfish and dust mite species in a clonally dependent manner.
• A more targeted therapeutic approach for allergic patients has the potential to address key allergens directly with better safety than allergen-oriented approaches and a quicker onset of action.

Click the button below to read the entire Press Release:

Continue Reading The Press Release